General Policy

IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.

One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: www.iiar-anticancer.org and www.iv.iiarjournals.org

Selection of Recent Articles

Proteomic Profiling to Identify Prognostic Biomarkers in Heart Failure. P.A. SCOTT, B. ZEIDAN, L.L. NG, M. ZEB, J.A. ROSENGARTEN, S. GARIBI, N.P. CURZEN, J.M. MORGAN, P.A. TOWNSEND (Southampton; Leicester, UK; Athens, Greece)

Diverging In Vitro Antibody Isotype Switching Preference in B-Lymphocytes from C57BL/6 and FVB Mice. A.G. PUTHIYAVEETIL, B. OKYERE, C.M. REILLY, D. CAUDELL (Blacksburg, VA, USA)

The Zebrafish - Danio rerio - Is a Useful Model for Measuring the Effects of Small-molecule Mitigators of Late Effects of Ionizing Irradiation. M.W. EPPERLY, N. BAHARY, M. QUADER, V. DEWALD, J.S. GREENBERGER (Pittsburgh, PA, USA)

Breast Cancer: Mechanisms Involved in Action of Phytoestrogens and Epigenetic Changes. A. DAGDEMIR, J. DURIF, M. NGOLLO, Y.-J. BIGNON, D. BERNARD-GALLON (Clermont-Ferrand, France)

Positron-emission Tomography (PET) Imaging Agents for Diagnosis of Human Prostate Cancer: Agonist vs. Antagonist Ligands. P.K. NANDA, B.E. WIENHOFF, T.L. ROLD, G.L. SIECKMAN, J. ROGERS, J. SMITH (Columbia; St. Louis, MO, USA)

In Vivo Models for Defining Molecular Subtypes of the Primitive Neuroectodermal Tumor Genome: Current Challenges and Solutions. J.D. LARSON, D.A. LARGAESPA (Minneapolis, MN, USA)

Effects of Minocycline on Hematopoietic Recovery After Whole-body Irradiation. S. MEHROTRA, M.J. PECAUT, D.S. GRIDLEY (Loma Linda, CA, USA)

Sequential Changes in the Expression of Wnt- and Notch-related Genes in the Vagina and Uterus of Ovariectomized Mice after Estrogen Exposure. T. NAKAMURA, S. MIYAGAWA, Y. KATSU, T. SATO, T. IGUCHI, Y. OHTA (Yamagata; Okazaki; Sapporo; Yokohama; Tottori, Japan)

Catecholamines Reduce Dose-dependent Oedema Formation and Inflammatory Reaction in an Isolated Rat Lung Model. C. DACHO, A. DACHO, A. GEISSLER, C. HAUSER, K. NOWAK, G. BECK (Heidelberg; Essen; Wiesbaden, Germany)

Biocompatibility of Membranes with Unrestricted Somatic Stem Cells. C. NAUJOKS, F. TRINKMANN, F. HEGEMANN, J. GRUETTNER, G. SCHMID-BINDERT, M. BORGGREFE, D. HAGHI, J. SAUR (Manneheim, Germany)

Acclimatization of Mice to Different Cage Types and Social Groupings with Respect to Fecal Secretion of IgA and Corticosterone Metabolites. C.J. BUNDGAARD, O. KALLIKIOSKI, K.S. ABELSON, J. HAU (Copenhagen, Denmark)

Exploring Anticarcinogenic Agents in a Rat Hepatocarcinogenesis Model – Focus on Selenium and Statins. L. BJÖRKHÉM-BERGMAN, L. EKSTRÖM, L.C. ERIKSSON (Stockholm, Sweden)


Amino Acid Chloramine Damage to Proliferating Cell Nuclear Antigen in Mammalian Cells. S.A. SALAMA, R.M. SNAPKA (Columbus, OH, USA; Cairo, Egypt)

The Effect of Insulin-like Growth Factor II in the Regulation of Tumour Cell Growth In Vitro and Tumourigenesis In Vivo. M. HALJE, M. NORDIN, D. BERGMAN, W. ENSGRÖM (Uppsala, Sweden)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST
Instructions to Authors 2013

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinasios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2013 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
A Selection of Recent Papers

Metastatic Biomarker Discovery Through Proteomics. L.T. BRINTON, T.A. BRENTNALL, J.A. SMITH, K.A. KELLY (Charlottesville, VA; Seattle, WA, USA)


Review: Breast Cancer and Metastasis: On the Way Toward Individualized Therapy. A.P. TRAPÊ, A.M. GONZALEZ-ANGULO (Houston, TX, USA)

In Silico Functional Profiling of Individual Prostate Cancer Tumors: Many Genes, Few Functions. I.P. GORLOV, J. BYUN, C.J. LOGOTHETIS (Houston, TX, USA)

Expression of Signal-induced Proliferation-associated Gene 1 (SIPA1), a RapGTPase-activating Protein, Is Increased in Colorectal Cancer and Has Diverse Effects on Functions of Colorectal Cancer Cells. K. JI, L. YE, A.-M. TOMS, R. HARGEST, T.A. MARTIN, F. RUGE, J. JI, W.G. JIANG (Cardiff, UK; Beijing, PR China)

Single Nucleotide Polymorphisms of Genes for EGF, TGF-β and TNF-α in Patients with Pancreatic Carcinoma. L. ZHANG, G. WU, F. HERRLE, M. NIEDERGETHMANN, M. KEESE (Frankfurt; Heidelberg, Germany; Xiamen, P.R. China)

Diagnostic MicroRNA Markers to Screen for Sporadic Human Colon Cancer in Blood. F.E. AHMED, N.C. AMED, P.W. VOS, C. BONNERUP, J.N. ATKINS, M. CASEY, G.J. NUOVO, W. NAZIRI, J.E. WILEY, R.R. ALLISON (Greenville, Goldsboro, NC; Columbus, OH, USA)

MGMT Hypermethylation and MDR System in Glioblastoma Cancer Stem Cells. V. CALDERA, M. MELLAI, L. ANNOVAZZI, O. MONZEGLIO, A. PIAZZI, D. SCHIFFER (Pavia; Novara, Italy)

20-HETE-producing Enzymes Are Up-regulated in Human Cancers. A. ALEXANIAN, B. MILLER, R.J. ROMAN, A. SOROKIN (Milwaukee, WI; Jackson, MS, USA)

Unifying the Genomics-based Classes of Cancer Fusion Gene Partners: Large Cancer Fusion Genes are Evolutionarily Conserved. L.M. PAVA, D.T. MORTON, R. CHEN, G. BLANCK (Tampa, FL, USA)
The mRNA Expression of Inhibitors of DNA Binding 1 and 2 is Associated with Advanced Tumor Stage and Adverse Clinical Outcome in Human Breast Cancer. U. WAZIR, W.G. JIANG, A.K. SHARMA, R.F. NEWBOLD, K. MOKBEL (London; Cardiff, Wales, UK) ................................................................. 2179

P14ARF Is Down-regulated During Tumor Progression and Predicts the Clinical Outcome in Human Breast Cancer. U. WAZIR, W.G. JIANG, H. YASAEI, H. LINNE, R.F. NEWBOLD, K. MOKBEL (London; Cardiff, Wales, UK) ................................................................. 2185


Relation Between Antibody to Hepatitis B Core Antigen and Survival after Curative Therapy for Non-B Non-C Hepatocellular Carcinoma. H. NISHIKAWA, Y. OSAKI, A. ARIMOTO, R. KITA, T. KIMURA (Osaka, Japan) ........................................................................................................... 2211

Normalization of Serum p53 Antibody Levels in Patients after Curative Resection for Colorectal Cancer. H. KAWAHARA, K. WATANABE, H. ENOMOTO, Y. TOYAMA, T. AKIBA, K. YANAGA (Chiba; Tokyo, Japan) ................................................................. 2217

Prognostic Factors For Male Breast Cancer: Similarity to Female Counterparts. E. YU, L. STITT, O. VUJOVIC, K. JOSEPH, A. ASSOULINE, J. AU, J. YOUNUS, F. PERERA, P. TAI (London, ON; Edmonton, AB; Regina, SK, Canada; Paris, France; Hong Kong, China) ................................................................. 2227

Relationship Between Circulating Tumor Cells and Peripheral T-Cells in Patients with Primary Breast Cancer. I. GRUBER, N. LANDENBERGER, A. STAEBLER, M. HAHN, D. WALLWIENER, T. FEHM (Tübingen; Freiburg, Germany) .................................................................................. 2233

Monitoring of Circulating Tumor Cells in Patients Undergoing Surgery for Hepatic Metastases from Colorectal Cancer. M. PESTA, J. FICHTL, V. KULDA, O. TOPOLCAN, V. TRESKA (Prague, Czech Republic) ........................................................................................................... 2239

ABSTRACTS OF THE 23rd ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO). 9-11 June, 2013, Florence, Italy ........................................................................................................... 2245

Errata ............................................................................................................................................ 2343

Book Reviews ................................................................................................................................ 2345

Announcements .............................................................................................................................. 2351

D-Dimer Elevation and Paresis Predict Thromboembolic Events During Bevacizumab Therapy for Recurrent Malignant Glioma. M. MISCH, M. CZABANKA, J. DENGLER, M. STOFFELS, G. AUF, P. VAJKOCZY, F. STOCKHAMMER (Berlin; Göttingen, Germany) ........................................................................... 2093


A Trial of Autologous Ex vivo-expanded NK Cell-enriched Lymphocytes with Docetaxel in Patients with Advanced Non-small Cell Lung Cancer as Second- or Third-line Treatment: Phase Ia Study. Y.J. YANG, J.C. PARK, H.K. KIM, J.H. KANG, S.Y. PARK (Daedeon; Suwon; Seoul, Republic of Korea) ............ 2115

Clinical Significance of Expression of Cancer/testis Antigen and Down-regulation of HLA Class-I in Patients with Stage I Non-small Cell Lung Cancer. T. HANAGIRI, Y. SHIGEMATSU, S. SHINOHARA, M. TAKENAKA, S. OKA, Y. CHIKAISHI, Y. NAGATA, T. BABA, H. URAMOTO, T. SO, S. YAMADA (Kitakyushu, Japan) ................................................................. 2123

KRAS Mutations in Patients with Colorectal Cancer As Detected by High-resolution Melting Analysis and Direct Sequencing. K. AKIYOSHI, Y. YAMADA, Y. HONMA, S. IWASA, K. KATO, T. HAMAGUCHI, Y. SHIMADA, H. TANIGUCHI, K. FURUTA (Tokyo, Japan) ................................................................ 2129


Radiation Therapy in the Treatment of HIV-related Kaposi’s Sarcoma. V. DONATO, R. GUARNACCIA, J. DOGNINI, G. DE PASCALIS, C. CARUSO, R. BELLAGAMBA, A. MORRONE (Rome, Italy) ........................................... 2153

Surgical Resection of Brain Metastases from Breast Cancer in the Modern Era: Clinical Outcome and Prognostic Factors. E. TABOURET, P. METELLUS, A. TALLET-RICHARD, D. FIGARELLA-BRANGER, E. CHARAFFE-JAUFFRET, P. VIENS, A. GONÇALVES (Marseille, France) ................................................................. 2159


Radiotherapy in the Management of Pancreatic Neuroendocrine Tumors (PNET): Experience at Three Institutions. M.W. SAIF, R. OVE, J. NG, S. RUSSO (Boston, MA; New York, NY; Mobile, AL, USA) .... 2175

Contents continued on the preceding page
Influence of Sex Differences on the Progression of Cancer-induced Bone Pain. S. FALK, M. ULDALL, C. APPEL, M. DING, A.-M. HEEGAARD (Copenhagen; Odense, Denmark) ................................................................. 1963


Mitogen-inducible Gene-2 (MIG2) and Migfilin Expression Is Reduced in Samples of Human Breast Cancer. V. GKRETSI, V. PAPANIKOLAOU, L.C. ZACHARIA, E. ATHANASSIOU, C. WU, A. TSEZOU (Larissa, Greece; Pittsburgh, PA, USA) ........................................................................................................ 1977

Characterization of Low Molecular Weight Protein Tyrosine Phosphatase Isoforms in Human Breast Cancer Epithelial Cell Lines. I. ALHO, L. COSTA, M. BICHO, C. COELHO (Lisbon, Portugal) ................................................................. 1983

Evaluation of Melphalan, Oxaliplatin, and Paclitaxel in Colon, Liver, and Gastric Cancer Cell Lines in a Short-term Exposure Model of Chemosaturation Therapy by Percutaneous Hepatic Perfusion. R.P. UZGARE, T.P. SHEETS, D.S. JOHNSTON (Queensbury, NY, USA) ........................................................................................................ 1989


Effects of Two Disiloxanes ALIS-409 and ALIS-421 on Chemoprevention in Model Experiments. H. TOKUDA, T. MAOKA, N. SUZUKI, J. HOHMANN, A. WASAS, H. ENGI, I. MUCSI, U. OLSZIEWSKI, G. HAMILTON, L. AMARAL, J. MOLNAR (Kanazawa; Kyoto, Japan; Szeged, Hungary; Vienna, Austria) ........................................ 2021

Regulation of Target Genes of PAX3–FOXO1 in Alveolar Rhabdomyosarcoma. E.H. AHN (Philadelphia, PA; Seattle, WA, USA) ........................................................................................................ 2029

Antifolate Response in Replication Arrest Mutants of Saccharomyces cerevisiae. K. DORNFELD (Duluth, MN, USA) ........................................................................................................ 2037

Comparison of Antitumor Effects of Native and Recombinant Human Interferon-α on Non-small Cell Lung Cancer Cells. G. ŠANTAK, M. ŠANTAK, D. FORČIĆ (Požega; Zagreb, Croatia) ........................................................................................................ 2043

Clinical Studies

Autologous Tumor Lysate-pulsed Dendritic Cell Immunotherapy for Pediatric Patients with Newly Diagnosed or Recurrent High-grade Gliomas. J.L. LASKY III, E.H. PANOSYAN, A. PLANT, T. DAVIDSON, W.H. YONG, R.M. PRINS, L.M. LIAU, T.B. MOORE (Torrance; Los Angeles, CA, USA) ........................................................................................................ 2047


VEGFR1 and NRP1 Endothelial Expressions Predict Distant Relapse after Radical Prostatectomy in Clinically Localized Prostate Cancer. M. TALAGAS, A. UGUEN, R. GARLANTEZEC, G. FOURNIER, L. DOUCET, E. GOBIN, P. MARCORELLES, A. VOLANT, M. DE BRAEKELEER (Brest, France) ........................................................................................................ 2065

Transarterial Chemoembolization Using DEBIRI for Treatment of Hepatic Metastases from Colorectal Cancer. G. NARAYANAN, K. BARBERY, R. SUTHAR, G. GUERRERO, G. ARORA (Miami, FL, USA) ........................................................................................................ 2077

Contents continued on the preceding page
The mTOR Inhibitor RAD001 Potentiates Autophagic Cell Death Induced by Temozolomide in a Glioblastoma Cell Line. E. JOSSET, H. BURCKEL, G. NOËL, P. BISCHOF (Strasbourg Cedex, France) ....................


Antiproliferative and Apoptosis-inducing Activity of Curcumin against Human Gallbladder Adenocarcinoma Cells. M. ONO, T. HIGUCHI, M. TAKESHIMA, C. CHEN, S. NAKANO (Fukuo, Japan) ..........................................................

The Indole-3-carbinol Cyclic Tetrameric Derivative CTet Synergizes with Cisplatin and Doxorubicin in Triple-negative Breast Cancer Cell Lines. M. DE SANTI, L. GALLUZZI, A. DURANTI, M. MAGNANI, G. BRANDI (Urbino, Italy) ............................................................................................................

Broussoflavonol B Restricts Growth of ER-negative Breast Cancer Stem-like Cells. M. GUO, M. WANG, X. ZHANG, H. DENG, Z.-Y. WANG (Omaha, NE, USA) ........................................................................

Changes in CO₂ Concentration Increase the Invasive Ability of Colon Cancer Cells. S. OBATA, T. GOI, T. NAKAZAWA, Y. KIMURA, K. KATAYAMA, A. YAMAGUCHI (Fukui, Japan) .............................................................


Increased Plasma Caveolin-1 Levels Are Associated with Progression of Prostate Cancer among Japanese Men. S. SUGIE, S. MUKAI, H. TSUKINO, Y. TODA, T. YAMAUCHI, I. NISHIKATA, Y. KURODA, K. MORISHITA, T. KAMOTO (Miyazaki; Tenri, Nara, Japan) ................................................................

Mutations in Adenosine Deaminase-like (ADAL) Protein Confer Resistance to the Antiproliferative Agents \( N_6 \)-Cyclopropyl-PMEDAP and GS-9219. C.R. FREY, G. ANDREI, I. VOTRUBA, C. CANNIZZARO, B. HAN, W. FUNG, M. HUNG, X. LIU, R. GELEZIUNAS, P. FITEN, G. OPDENAKKER, R. SNOECK, T. CIHLAR (Foster City, CA, USA; Leuven, Belgium; Prague, Czech Republic) .............................................................

Angiogenesis of Lung Cancer Utilizes Existing Blood Vessels Rather than Developing New Vessels Using Signals from Carcinogenesis. H. URAMOTO, S. YAMADA, F. TANAKA (Kitakyushu, Japan) .............................................................

Expression of Bone Morphogenetic Protein-10 (BMP10) in Human Urothelial Cancer of the Bladder and its Effects on the Aggressiveness of Bladder Cancer Cells In Vitro. N. ZHANG, L. YE, L. WU, X. DENG, Y. YANG, W.G. JIANG (Beijing; Xinjiang, P.R. China; Cardiff, UK) .............................................................


Quercetin Inhibits Migration and Invasion of SAS Human Oral Cancer Cells through Inhibition of NF-\( \kappa \)B and Matrix Metalloproteinase-2/9 Signaling Pathways. W.-W. LAI, S.-C. HSU, F.-S. CHUEH, Y.-Y. CHEN, J.-S. YANG, J.-P. LIN, J.-C. LIEN, C.-H. TSAI, J.-G. CHUNG (Taichung, Taiwan, ROC) .............................................................

Chemotherapeutic Alteration of VEGF, PDGF and PDGFRα/β Expression Under 5-FU vs. Docetaxel in HPV-transformed Squamous Cell Carcinoma Compared to HPV-negative HNSCC In Vitro. C. ADERHOLD, C. UMBREIT, A. FABER, A. SAUTER, J.U. SOMMER, R. BIKR, P. ERBEN, R.-D. HOFHEINZ, J. STERNSTRAETER, K. HÖRMANN, J.D. SCHULTZ (Mannheim, Germany) .............................................................